It was a pleasure to meet with Kelly Dooley (Johns Hopkins University School of Medicine, Baltimore, MD, USA) to discuss the major challenges to developing new treatment regimens for drug-resistant tuberculosis.
The session entitled: ‘New drugs and new regimens for treating drug-resistant tuberculosis’ was presented at the 31st European Congress of Clinical Microbiology & Infectious Diseases (ECCMID).
Questions:
- Could you give us a brief overview of drug-resistant tuberculosis, its global burden and the urgency of the need for new treatments? (0:25)
- What are the major challenges to developing new treatment regimens and how may these be overcome? (1:50)
- What are the challenges in treating tuberculosis in HIV-positive people? (3:19)
- What are the recommended treatment regimens for multi drug resistant tuberculosis? (4:50)
Disclosures: Kelly Dooley has nothing to disclose in relation to this video.
Support: Interview and filming supported by Touch Medical Media. Interview conducted by Katey Gabrysch.
Filmed as a highlight of ECCMID , Virtual 2021.
